Echo Therapeutics, Inc. ECTE, a medical device company developing its needle-free Symphony® CGM
System as a non-invasive, wireless, continuous glucose monitoring system,
announced that the independent members of the Board of Directors and Mr.
Robert F. Doman, the Executive Chairman and Interim Chief Executive Officer,
today sent a letter to its shareholder, Platinum-Montaur Life Sciences, LLC,
in response to an August 30, 2013 public communication made by
Platinum-Montaur and its affiliated funds. In addition, Echo has communicated
with Platinum-Montaur to discuss the matters raised in the August 30, 2013
communication. The Company and Platinum-Montaur have scheduled a meeting for
next week.
As Echo has previously announced, it continues to consider and seek to enter
into collaborations or licenses regarding the future development and
distribution of its products and remains willing to enter into discussions
regarding potential collaborations or licenses.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in